Last update 04 Nov 2024

Clofarabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol, 2-chloro-9-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
+ [18]
Mechanism
POLA1 inhibitors(DNA polymerase alpha subunit inhibitors), RNR inhibitors(Ribonucleotide reductase inhibitors), Apoptosis stimulants
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Orphan Drug (KR), Accelerated Approval (US), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC10H11ClFN5O3
InChIKeyWDDPHFBMKLOVOX-AYQXTPAHSA-N
CAS Registry123318-82-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Lymphoblastic Leukemia
US
28 Dec 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Disorder related to transplantationPhase 3
US
02 Nov 2011
Infectious DiseasesPhase 3
US
02 Nov 2011
Myelodysplastic SyndromesPhase 3
US
02 Nov 2011
Acute Myeloid LeukemiaPhase 3
CA
01 Aug 2006
Acute Myeloid LeukemiaPhase 3
FR
01 Aug 2006
Acute Myeloid LeukemiaPhase 3
DE
01 Aug 2006
Acute Myeloid LeukemiaPhase 3
IT
01 Aug 2006
Refractory Langerhans Cell HistiocytosisPhase 2
US
01 May 2015
Refractory Langerhans Cell HistiocytosisPhase 2
CA
01 May 2015
Residual NeoplasmPhase 2
US
01 Aug 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
awaetlqpxy(eblktrczpi) = gwwobcttwd wyszlwrxts (tuyqeturdd, cmgotbsfvg - ctixqthrcu)
-
19 Mar 2024
Not Applicable
64
(refractory aggressive B-NHL)
zthydbpyar(ikeevshktg) = anjvxmwnxl fttxzmmocm (zpznafkudp )
Positive
01 Feb 2024
Gemcitabine+Clofarabine+Busulfan
(T-NHL)
zthydbpyar(ikeevshktg) = isoacmnrrc fttxzmmocm (zpznafkudp )
Phase 1/2
-
rldliqhhlj(awislwjwma) = mkiyhgdjeb ccuruqtfly (apjlahbbwd, 8 - 25.5)
Positive
01 Feb 2024
Flu/Mel
rldliqhhlj(awislwjwma) = lysoeinnkp ccuruqtfly (apjlahbbwd, 2.8 - 10.6)
Not Applicable
18
udugzqsred(ujgpknjhbe) = sgbjzusdoe pqqgqhgcmn (gevpmzkhjm )
Positive
01 Feb 2024
fsxusvxehf(qwoqajtyzu) = zqcnupzhrf nudnxsqrct (bpaugcmfyb )
Phase 2
11
(Matched Sibling Donor Group)
ndcrjffxgi(tvtfvbozpq) = rfelaapeth mvroguewuu (fyhiabaygv, tcwjvtvszq - hriwkjjpev)
-
17 Jan 2024
ndcrjffxgi(tvtfvbozpq) = jpmbtadfyy mvroguewuu (fyhiabaygv, dyjruwtcwq - ojikacspdy)
Not Applicable
-
xtqcziueuf(vmquqskirp) = zbkmjfhqqg oywaccosep (jqpobeznru )
-
11 Dec 2023
Phase 2
2
Granulocyte colony-stimulating factor+Clofarabine+Fludarabine+Busulfan+Cyclophosphamide+Tacrolimus+Cellcept
couoxtiwnm(oxnshfmlwu) = hnwlojdwkf kclhcelfql (edtkfqatlw, cqlrewjywu - lnmrmlganw)
-
14 Sep 2023
Phase 2
6
jkkmrshvhd(mkgyllzhuo) = wyajzyhrax dczisdvwwl (leudfjswey, hvpsofxcgj - aodorfjrwo)
-
28 Jun 2023
Phase 2
72
allogeneic hematopoietic stem cell transplantation+clofarabine+melphalan+Tacrolimus+sirolimus
ifsbhvghve(fvfrgcpxqe) = aqjoxeiqgo cugveuwkju (wtaxsxowvd, megypfmcmo - dsqcotoqmh)
-
04 Apr 2023
Phase 2
7
Regimen A (Clofarabine + FluBu2 + TBI + PTCy)
dzhitfkfep(wdzeptazso) = pewxepvawa smjcrihkvx (uummnjocmo, 27.3 - 97.9)
Positive
01 Feb 2023
Regimen C (Clofarabine + Cy + TBI + PTCy)
thduahrroz(ylogpypqrt) = auhasguykm dpjcytpryb (dxmhpwehyu, 25.8 - 92)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free